Gennex Laboratories reported a consolidated net profit of ₹2097.88 lacs for the financial year ended March 31, 2026, an increase from ₹1812.49 lacs in the prior year. Revenue from operations rose to ₹17274.09 lacs from ₹13790.30 lacs in FY25. The board approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, at a meeting held on May 30, 2026.

The company’s standalone net profit for FY26 was ₹1612.81 lacs, compared to ₹1403.68 lacs in the previous year. Standalone revenue from operations increased to ₹11985.67 lacs from ₹9457.79 lacs. The profit attributable to owners of the parent on a standalone basis was ₹1618.00 lacs.

Consolidated Financial Performance

The consolidated financial results for the year show growth across key metrics. Total income for FY26 was ₹18098.67 lacs, up from ₹14833.31 lacs in the previous year. Total expenses for the period amounted to ₹15714.90 lacs, compared to ₹12678.35 lacs in FY25.

Auditor's Observations

R Pugalia and Company, the statutory auditors, issued a qualified opinion in the audit report. The auditors noted that management had assured to obtain confirmations and reconciliations for balances of current assets, non-current assets, and liabilities, but the impact of this remains unascertained. Additionally, the company is in the process of installing Transaction Traceability Software in its accounting systems.

The Statement on Impact of Audit Qualifications confirmed that the impact of the qualification could not be ascertained. Management stated that the company had made efforts to obtain confirmations for advances, deposits, unsecured loans, trade receivables, and trade payables before signing the accounts. The company confirmed that the balances shown in the books are true and correct to the best of its knowledge.

Segment Reporting

The company operates in a single reportable segment: Bulk Drugs, Biotech Products, and Intermediates. Geographically, India remains the largest market, generating revenue of ₹8402.32 lacs in FY26, up from ₹6215.29 lacs in the previous year. Vietnam was the next largest market with revenue of ₹1346.70 lacs, followed by Colombia at ₹917.04 lacs.

Gennex Laboratories Limited has announced that its board of directors will meet on Saturday, May 30, 2026. The primary agenda of the meeting is to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, along with the report of the statutory auditors.

The meeting is scheduled to take place at the corporate office of the company located at Akash Ganga, 04th Floor, Plot No.144, Srinagar Colony, Hyderabad – 500 073, Telangana State, India. The proceedings will be conducted in compliance with Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company has intimated the stock exchanges regarding the meeting. The notice was published in both Business Standard and Saksham (Local-Telugu) newspapers on May 20, 2026. The official notice is also available on the company's website and the BSE Limited website for shareholder reference.

The adoption of the audited financial results for the full fiscal year and the fourth quarter is a key regulatory requirement. Shareholders and investors can access the detailed results once they are approved and officially filed following the board meeting.